Studying Tocilizumab (study drug) in Patients With Severe COVID-19 Pneumonia
The purpose of this study is to evaluate the safety and effectiveness of the medication tocilizumab for adult patients with severe COVID-19 related pneumonia.
This research study is led by Dr. Daniel Skiest.
Contact: Lori Kozikowski, 413-794-5584
Primary Sponsor: Hoffmann-La Roche
April 06, 2020
Baystate Medical Center, 759 Chestnut Street, Springfield, MA
Hospitalized with COVID-19 pneumonia confirmed per WHO criteria (including a positive PCR of any specimen; e.g., respiratory, blood, urine, stool, other bodily fluid) and evidenced by chest X-ray or CT scan.
Total time in the study will be about 60 days.